Oncolytic virus therapies

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Tumor immunology

Background:

• Oncolytic viruses (OVs) are a promising cancer treatment modality with dual anticancer mechanisms: direct tumor cell lysis and immune system activation.
• The immune-stimulating aspect of OVs provides a multi-target approach against various tumor-associated antigens.
• Since the 2005 approval of Oncorine™, the first human OV therapy, global patent filings and clinical studies have significantly increased.

Purpose of the Study:

• To review patents and clinical studies of leading oncolytic virus (OV) products.
• To analyze the advantages and disadvantages of OV therapy.
• To highlight current research and clinical applications of OVs in various cancers.

Main Methods:

• Patent landscape analysis of OV products.
• Review of clinical trial data (Phase I/II) for OV therapies.
• Assessment of systemic and intratumoral injection methods.

Main Results:

• Over 200 patents filed worldwide indicate significant global interest in OV technology.
• Clinical studies, including those for hepatocellular carcinoma, melanoma, and glioblastoma, show encouraging but transient efficacy.
• Combined treatment strategies involving OVs with radio- or chemotherapy are under investigation.

Conclusions:

• Oncolytic virus therapy presents a promising, innovative approach to cancer treatment with dual mechanisms of action.
• Current clinical results are encouraging, supporting further development and optimization of OV therapies.
• Combination therapies hold potential for enhancing the long-term effectiveness of OV treatments.